Thus, further studies are required to profile the mutational landscape of DNMT genes and assess whether such mutations, if detected, are associated with the global hypermethylation patterns of breast cancer patients in our cohort, particularly those with TNBC and luminal B-HER2 subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.